(-)-(6AS,13BR)-11-CHLORO-6,6A,7,8,9,13B-HEXAHYDRO-7-METHYL-5H-BENZO(D)NAPHTH(2,1-B)AZEPIN-12-OL
Lesch-Nyhan Disease
Emalex Biosciences Inc.Small moleculePhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Lesch-Nyhan Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aminomidazole Carboxamide Riboside National Center for Research Resources (NCRR) | Phase 2 | B |
(6S)-L-ERYTHRO-TETRAHYDROBIOPTERIN University of California, San Diego | Phase 2/3 | B |
Same molecule, other indications
(-)-(6AS,13BR)-11-CHLORO-6,6A,7,8,9,13B-HEXAHYDRO-7-METHYL-5H-BENZO(D)NAPHTH(2,1-B)AZEPIN-12-OL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →